50% of the AIDS virus (HIV-1) protein components in order to stimulate
a broad anti-HIV immune response. The vaccines cannot cause AIDS
because they do not include complete virus. A Phase 1 human trial,
started in April 2006, evaluated the delivery of only 1/10th of the
full dosage and utilized the same vaccine regimen evaluated in the full
From data collected from the 26 participants who completed the trial,
the following positive conclusions were observed:
-- GeoVax HIV/AIDS vaccines, both DNA and MVA, continue to demonstrate
that they are quite safe and immunogenic following the delivery of
the four full-doses (two of each vaccine) used in the trial's
-- The full-dose regimen of GeoVax vaccines continues to be well
tolerated without any type of reaction, mild or systemic, in the
majority of participants.
-- CD4 T-cell responses are high in both the low and full-dose regimens,
84% and 78% of participants.
-- CD8 T-cell responses are present in 42% of the full-dose recipients
and 33% of the 1/10th dose recipients.
-- Antibody responses to the envelope glycoprotein (Env) increased
following the fourth vaccination, and were present in 88% of the
-- Delivery of the fourth vaccination increased the frequency and
magnitude of the CD8 T-cell and Antibody responses.
-- During November 2007 through January 2008, GeoVax raised approximately
$3 million in equity capital through a series of privately negotiated
transactions with individual accredited investors and one institutional
investor. These funds, along with the funds received pursuant to the
NIH grant discussed above will be used to offset the Company's ongoing
research and development costs and
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved